GlassScriptPhysician profile
George K Tomy
NPI 1265426480
$6,796.04
in general payments reported to CMS, 2019-2025
35 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,685 · 2020: $448 · 2021: $920 · 2022: $1,935 · 2023: $1,808.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,808.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,807.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $765.63 | 2021-2023 | Viberzi, Qulipta, Linzess |
| Astellas Pharma US INC | $757.22 | 2019-2023 | Veozah, Myrbetriq |
| Novo Nordisk INC | $641.32 | 2019-2023 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $581.81 | 2019-2023 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $430.08 | 2019-2023 | |
| Glaxosmithkline, LLC. | $420.68 | 2019-2023 | Shingrix, Arexvy, Trelegy Ellipta |
| Lilly USA, LLC | $346.36 | 2019-2023 | Mounjaro, Jardiance, Emgality |
| Boehringer Ingelheim Pharmaceuticals, INC. | $337.63 | 2019-2023 | Jardiance, Synjardy |
| Amgen INC. | $305.20 | 2019-2023 | Repatha, Otezla, Evenity |
| Bayer Healthcare Pharmaceuticals INC. | $272.90 | 2022-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $206.81 | 2019-2022 | |
| Amarin Pharma, INC. | $205.28 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $202.13 | 2019-2023 | Belsomra, Steglatro, Steglujan |
| Janssen Pharmaceuticals, INC | $166.61 | 2019-2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $155.21 | 2019-2023 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $116.35 | 2022-2023 | Nayzilam |
| Biohaven Pharmaceutical Holding Company LTD. | $103.62 | 2022 | |
| Sk Life Science, INC. | $99.07 | 2023 | |
| Sanofi-Aventis U.S. LLC | $89.10 | 2019-2021 | |
| Shield Therapeutics INC | $86.41 | 2023 | Accrufer |
| Takeda Pharmaceuticals U.S.A., INC. | $74.42 | 2021-2022 | |
| Abbott Laboratories | $62.89 | 2023 | Freestyle Libre 3 |
| Sunovion Pharmaceuticals INC. | $44.82 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $39.14 | 2021 | |
| Lundbeck LLC | $37.46 | 2022 | |
| Neurelis, INC. | $34.56 | 2023 | Valtoco |
| Allergan, INC. | $33.46 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $32.32 | 2022-2023 | Quviviq |
| Almatica Pharma LLC | $31.82 | 2021 | |
| Dynavax Technologies Corporation | $29.68 | 2022 | |
| Exact Sciences Corporation | $28.03 | 2023 | Cologuard Collection Kit |
| Eisai INC. | $17.28 | 2021 | |
| Seqirus USA INC | $14.09 | 2022 | |
| Smith+Nephew, INC. | $13.66 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $12.99 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Tomy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.